120 related articles for article (PubMed ID: 29317067)
21. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
Coune PG; Bensadoun JC; Aebischer P; Schneider BL
J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
[TBL] [Abstract][Full Text] [Related]
22. [Pathological mechanisms of Parkinson's disease].
Matsui H; Takahashi R
Brain Nerve; 2009 Apr; 61(4):441-6. PubMed ID: 19378814
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein E and LRP1 Increase Early in Parkinson's Disease Pathogenesis.
Wilhelmus MM; Bol JG; Van Haastert ES; Rozemuller AJ; Bu G; Drukarch B; Hoozemans JJ
Am J Pathol; 2011 Nov; 179(5):2152-6. PubMed ID: 21907175
[TBL] [Abstract][Full Text] [Related]
25. Neuromelanin in Parkinson's Disease: Tyrosine Hydroxylase and Tyrosinase.
Nagatsu T; Nakashima A; Watanabe H; Ito S; Wakamatsu K
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456994
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotective effect of combined therapy with hyperbaric oxygen and madopar on 6-hydroxydopamine-induced Parkinson's disease in rats.
Pan X; Chen C; Huang J; Wei H; Fan Q
Neurosci Lett; 2015 Jul; 600():220-5. PubMed ID: 26101828
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of α-synuclein in aged human brain associated with neuromelanin accumulation.
Xuan Q; Xu SL; Lu DH; Yu S; Zhou M; Uéda K; Cui YQ; Zhang BY; Chan P
J Neural Transm (Vienna); 2011 Nov; 118(11):1575-83. PubMed ID: 21461961
[TBL] [Abstract][Full Text] [Related]
28. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
29. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
[TBL] [Abstract][Full Text] [Related]
30. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
Shannon KM; Keshavarzian A; Mutlu E; Dodiya HB; Daian D; Jaglin JA; Kordower JH
Mov Disord; 2012 May; 27(6):709-15. PubMed ID: 21766334
[TBL] [Abstract][Full Text] [Related]
31. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
[TBL] [Abstract][Full Text] [Related]
32. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.
Chu Y; Mickiewicz AL; Kordower JH
Neurobiol Dis; 2011 Jan; 41(1):71-82. PubMed ID: 20816781
[TBL] [Abstract][Full Text] [Related]
33. TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.
Nam JH; Park ES; Won SY; Lee YA; Kim KI; Jeong JY; Baek JY; Cho EJ; Jin M; Chung YC; Lee BD; Kim SH; Kim EG; Byun K; Lee B; Woo DH; Lee CJ; Kim SR; Bok E; Kim YS; Ahn TB; Ko HW; Brahmachari S; Pletinkova O; Troconso JC; Dawson VL; Dawson TM; Jin BK
Brain; 2015 Dec; 138(Pt 12):3610-22. PubMed ID: 26490328
[TBL] [Abstract][Full Text] [Related]
34. Activation of the unfolded protein response in Parkinson's disease.
Hoozemans JJ; van Haastert ES; Eikelenboom P; de Vos RA; Rozemuller JM; Scheper W
Biochem Biophys Res Commun; 2007 Mar; 354(3):707-11. PubMed ID: 17254549
[TBL] [Abstract][Full Text] [Related]
35. What process causes nigral cell death in Parkinson's disease?
Jenner P
Neurol Clin; 1992 May; 10(2):387-403. PubMed ID: 1584181
[TBL] [Abstract][Full Text] [Related]
36. New face of neuromelanin.
Double KL; Halliday GM
J Neural Transm Suppl; 2006; (70):119-23. PubMed ID: 17017518
[TBL] [Abstract][Full Text] [Related]
37. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
[TBL] [Abstract][Full Text] [Related]
38. Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy.
Engeln M; Ansquer S; Dugast E; Bezard E; Belin D; Fernagut PO
Neuropharmacology; 2016 Oct; 109():69-77. PubMed ID: 27216859
[TBL] [Abstract][Full Text] [Related]
39. Alpha-synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease.
Hasegawa T; Matsuzaki-Kobayashi M; Takeda A; Sugeno N; Kikuchi A; Furukawa K; Perry G; Smith MA; Itoyama Y
FEBS Lett; 2006 Apr; 580(8):2147-52. PubMed ID: 16567160
[TBL] [Abstract][Full Text] [Related]
40. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
